Short answer
Johnson & Johnson (JNJ) filed its Q2 2026 10-Q quarterly report on Jul 23, 2026 for the quarter ended Jun 28, 2026. Quarterly revenue was $25.3B (up 6.6% year over year) with net income of $5.5B.
Q2 2026 key financials · XBRL
- Revenue
- $25.3B
- +6.6% YoY · +5.2% QoQ
- Net income
- $5.5B
- −0.1% YoY · +5.7% QoQ
- Gross margin
- 68.2%
- EPS (diluted)
- $2.27
- −0.4% YoY · +6.1% QoQ
Source: XBRL data from the Johnson & Johnson (JNJ) Q2 2026 10-Q on SEC EDGAR. USD.
Johnson & Johnson Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $25.3B, up 6.6% YoY from $23.7B, with operational growth of 5.6%
- Q2 operating profitability 26.7% vs 27.3% YoY; segment margin 29.3% vs 28.5%
- Best segment Innovative Medicine revenue $16.4B, up 7.8%; worst MedTech margin 13.2% vs 14.1% YoY
- Cash, equivalents and current securities $20.8B vs $18.9B YoY; debt $49.0B vs $50.8B
- Headwinds: STELARA biosimilars, SIMPONI European competition and OPSUMIT U.S. generics likely reducing future sales
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Johnson & Johnson quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.